David Taber to Risk Assessment
This is a "connection" page, showing publications David Taber has written about Risk Assessment.
Connection Strength
0.528
-
A Critical Analysis of the Specific Pharmacist Interventions and Risk Assessments During the 12-Month TRANSAFE Rx Randomized Controlled Trial. Ann Pharmacother. 2022 06; 56(6):685-690.
Score: 0.123
-
Development and future deployment of a 5 years allograft survival model for kidney transplantation. Nephrology (Carlton). 2019 Aug; 24(8):855-862.
Score: 0.105
-
Morbid obesity and functional status as predictors of surgical complication after renal transplantation. Am J Surg. 2018 Apr; 215(4):663-668.
Score: 0.092
-
Inclusion of dynamic clinical data improves the predictive performance of a 30-day readmission risk model in kidney transplantation. Transplantation. 2015 Feb; 99(2):324-30.
Score: 0.078
-
Joint effect of race/ethnicity or location of residence and sex on low density lipoprotein-cholesterol among veterans with type 2 diabetes: a 10-year retrospective cohort study. BMC Cardiovasc Disord. 2020 10 15; 20(1):449.
Score: 0.029
-
Impact of Type 1 and Type 2 Diabetes Mellitus on Pancreas Transplant Outcomes. Exp Clin Transplant. 2019 12; 17(6):796-802.
Score: 0.025
-
Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types. Transplantation. 2018 09; 102(9):1440-1452.
Score: 0.025
-
Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatr Transplant. 2016 Feb; 20(1):44-8.
Score: 0.021
-
The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients. Transplant Proc. 2012 Jun; 44(5):1323-8.
Score: 0.016
-
Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation. 2010 May 27; 89(10):1218-23.
Score: 0.014